WebPurify Appoints Head of Trust & Safety in EMEA in Response to Rising Regional Regulatory Demands
Ailís Daly has joined WebPurify as Head of Trust & Safety, EMEA, as it expands the company's services in the region. The appointment is in response to the growing regulatory demands and increased need for robust content moderation across digital platforms in EMEA.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003715648/en/
WebPurify Hires Ailís Daly, Former TikTok Head of Violence & Aggression Issue Policies (Photo: WebPurify)
This strategic move will help WebPurify’s clients align with key regulations such as the EU’s Digital Services Act (DSA) and the UK's Online Safety Act, ensuring compliance while fostering safer online environments for users and businesses alike. Ailís will also focus on enhancing partnerships with European clients and strengthening WebPurify’s market position.
Based in Ireland, a European tech hub, Ailís joins WebPurify from TikTok, where she was Global Head of Violence & Aggression Issue Policies – a position she’s held since 2021, and that followed other senior roles at Airbnb, Twitter, and Google, in policy and risk management.
“WebPurify has a strong reputation of being industry veterans,” says Ailís, “and the timing is critical as companies operating online in Europe need to navigate many recent regulatory requirements launched under the EU’s Digital Services Act (DSA) and other legislation related to online safety. Failure to comply may result in significant costs to a company, both monetarily and reputationally.”
WebPurify’s clients will benefit from enhanced regional support, ensured compliance with local regulations, and strengthened partnerships. The business will also expand its trust and safety consulting offering, which includes everything from community guidelines development to end-to-end risk audits.
“We’re thrilled to be expanding our team with the regional and professional expertise Ailís will bring,” says WebPurify VP of Trust & Safety, Alexandra Popken. “The rapid success of our Trust & Safety consultancy has encouraged us to broaden our reach. We’re committed to ensuring that WebPurify’s European clients not only meet regulatory standards but also rise to the growing challenge of creating safer online communities.”
About WebPurify
The leading moderation service, WebPurify combines the power of AI and human moderators to keep 1 in 7 Fortune 100 companies and their communities safe. As the first UGC moderation platform, WebPurify makes moderation accessible to businesses of all sizes, offering a range of solutions from plug-and-play to custom enterprise moderation. Founded in 2006, WebPurify is proud to be the first responders of the internet, protecting vulnerable groups from illicit content and supporting law enforcement in removing the worst offenders from our digital spheres. For additional information, visit: www.webpurify.com.
INTERVIEWS AVAILABLE
Ailís Daly, Head of Trust & Safety, EMEA
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003715648/en/
Contacts
WebPurify
Josh Buxbaum
877-751-4046 Ext 714
media@webpurify.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 22:46:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 22:35:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 21:32:00 EET | Press release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 14:00:00 EET | Press release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 14:00:00 EET | Press release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom